DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer
- 4 April 2011
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 47 (12), 1817-1825
- https://doi.org/10.1016/j.ejca.2011.02.024
Abstract
No abstract availableKeywords
Funding Information
- Wilhelm-Sander-Stiftung (Neustadt a.d. Donau, Germany) (2006.035-1)
- Deutsche Krebshilfe Mildred Scheel Stiftung (Bonn, Germany) (108524)
This publication has 34 references indexed in Scilit:
- Epigenetics and cancer treatmentEuropean Journal of Pharmacology, 2009
- Epigenetics in CancerNew England Journal of Medicine, 2008
- Methylation of Tumor-Related Genes in Neoadjuvant-Treated Gastric Cancer: Relation to Therapy Response and Clinicopathologic and Molecular FeaturesClinical Cancer Research, 2007
- Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal CancerNew England Journal of Medicine, 2006
- Recent advances in multimodal treatment for gastric cancer: a reviewGastric Cancer, 2005
- Increased DNA Methyltransferase 1 (DNMT1) Protein Expression Correlates Significantly with Poorer Tumor Differentiation and Frequent DNA Hypermethylation of Multiple CpG Islands in Gastric CancersThe American Journal of Pathology, 2004
- DNMT1 and DNMT3b cooperate to silence genes in human cancer cellsNature, 2002
- Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxirubicin, and cisplatinumCancer, 2001
- The effect of chromatin structure on cisplatin damage in intact human cellsNucleic Acids Research, 2000
- Differential mRNA expression of the human DNA methyltransferases (DNMTs) 1, 3a and 3b during the G0/G1 to S phase transition in normal and tumor cellsNucleic Acids Research, 2000